Implementation of pharmaceutical care to oncology patients using capecitabine
Keywords:
Descritores: Neoplasias da mama, Atenção farmacêutica, Capecitabina.Abstract
Objective: To describe the pharmaceutical care implementation results in patients using capecitabine for metastatic breast cancer treatment, in a public hospital in the South of Brazil.
Methods: The study was design as a observational cohort of patients diagnosed with metastatic breast cancer and treated with capecitabine during the period from September 2012 to April 2013. The pharmaceutical care model comprised interviews, analysis of drug related problems (DRP), case management (including pharmaceutical interventions, as required) and follow-up assessment.
Results: Thirty one patients were included in this study, whereas during this period 11 patients discontinued capecitabine. The patients underwent on average 13.7 (± 16.6) cycles of treatment (minimum 2 and maximum 92), when 158 interviews were performed (5 ± 2.4 / patient) and were identified 289 DRP. Of these, 82.7% represented adverse drug reactions (ADR). We identified 35 different kinds of ADR, of which the most frequent were hand-foot syndrome (42.2%), followed by nausea (8.8%) and skin hyperpigmentation (7.1%). Regarding ADR severity, 82.8% were classified as grade 1, 16.3% as grade 2 and 0.8% as grade 3. Several pharmaceutical interventions were performed (n=197), with the acceptance rate of 80.3%.
Conclusion: The model proposed in this study was effective in identifying PRM, allowing pharmaceutical interventions and preventive management, mostly accepted. However, it must be reinforced the need for further studies with appropriate design to establish an adequate safety profile of capecitabine.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
